Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KYNU | Q16719 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930559 | 1.00 | MBOAT4 (0.58) | MBOAT4ALDH1A1TRPM8ALOX15KYNU | |
| SCHEMBL22747610 | 1.00 | MBOAT4 (0.58) | MBOAT4ALDH1A1TRPM8ALOX15KYNU | |
| SCHEMBL8173806 | 0.91 | CTRB1 (0.54) | MBOAT4CTRB1ATMCTSKLMNA | |
| SCHEMBL7372388 | 0.91 | CTRB1 (0.54) | MBOAT4CTRB1ATMCTSKLMNA | |
| SCHEMBL17280899 | 0.89 | ALDH1A1 (0.53) | MBOAT4ALDH1A1ALOX15CTRB1ATM | |
| SCHEMBL22118319 | 0.88 | CTRB1 (0.54) | MBOAT4CTRB1ATMCTSKLMNA | |
| SCHEMBL14769904 | 0.88 | CTRB1 (0.54) | MBOAT4CTRB1ATMCTSKLMNA | |
| SCHEMBL29014283 | 0.87 | SYK (0.57) | MBOAT4CTRB1ATMCTSKLMNA | |
| SCHEMBL25875351 | 0.87 | SYK (0.57) | MBOAT4CTRB1ATMCTSKLMNA | |
| SCHEMBL8232784 | 0.86 | MBOAT4 (0.51) | MBOAT4CTRB1ATMCTSKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118108633-A | Preparation method of L-glufosinate intermediate (S) -2- (((benzyloxy) carbonyl) amino) but-3-enoic acid methyl ester | 浙江工业大学 | 2024-05-31 | — | — | CN | claimed |
| CN-118108633-A | Preparation method of L-glufosinate intermediate (S) -2- (((benzyloxy) carbonyl) amino) but-3-enoic acid methyl ester | 浙江工业大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-118108633-A | Preparation method of L-glufosinate intermediate (S) -2- (((benzyloxy) carbonyl) amino) but-3-enoic acid methyl ester | 浙江工业大学 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023194895-A1 | PYRROL DERIVATIVES AS INHIBITORS OF APOLIPOPROTEIN L-1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-12 | — | — | WO | disclosed |
| US-9434762-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | UNIVERSITY OF CANTERBURY (NZ) | 2016-09-06 | — | — | US | disclosed |
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | LINCOLN UNIVERSITY (NZ) | 2014-07-10 | — | — | US | disclosed |
| US-8710178-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | LINCOLN UNIVERSITY (NZ) | 2014-04-29 | — | — | US | disclosed |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | UNIVERSITY OF CANTERBURY (NZ) | 2011-01-27 | — | — | US | disclosed |
| US-20100137258-A1 | THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2183258-A2 | THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR USE AS AGONISTS OR ANTAGONISTS FOR METABOTROPIC GLUTAMATE RECEPTORS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009016520-A2 | THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR USE AS AGONISTS OR ANTAGONISTS FOR METABOTROPIC GLUTAMATE RECEPTORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008048121-A2 | MACROCYCLIC CYSTEINE PROTEASE INHIBITORS AND COMPOSITIONS THEREOF | LINCOLN UNIVERSITY (NZ) | 2008-04-24 | — | — | WO | disclosed |
| EP-0546566-B1 | Process for the preparation of L-phosphinothricine and its derivatives | HOECHST SCHERING AGREVO GMBH (DE) | 1996-09-04 | — | — | EP | disclosed |
| US-5420329-A | Process for the preparation of L-phosphinothricin and its derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-30 | — | — | US | disclosed |
| EP-0546566-A1 | Process for the preparation of L-phosphinothricine and its derivatives | Hoechst Schering AgrEvo GmbH (DE) | 1993-06-16 | — | — | EP | disclosed |
| EP-0209237-A2 | Vinyl-glycyl-amino-beta-lactam derivatives | BEECHAM GROUP PLC (GB) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137258-A1 | THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | C1R, TLR9, CBR1 | MBOAT4 1249/4885ALDH1A1 2913/4885TRPM8 639/4885 |
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | MBOAT4 3225/4885ALDH1A1 4230/4885TRPM8 1470/4885 |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | MBOAT4 3225/4885ALDH1A1 4230/4885TRPM8 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.